Demyelinating disease in SLE: is it multiple sclerosis or lupus?

Area of Science:

• Neuroimmunology
• Rheumatology
• Neurology

Background:

• Demyelinating syndromes and myelopathy are under-recognized central nervous system (CNS) manifestations of systemic lupus erythematosus (SLE).
• These SLE-related CNS conditions are frequently misdiagnosed as multiple sclerosis (MS) or other demyelinating disorders.
• Neurological symptoms can precede other SLE manifestations, complicating early diagnosis.

Purpose of the Study:

• To review the clinical, pathophysiological, radiological, and therapeutic aspects of CNS demyelinating disease in SLE.
• To highlight the challenges in differentiating SLE-associated demyelination from MS.
• To discuss the role of diagnostic tests and ongoing debates, such as antiphospholipid antibodies in SLE-associated transverse myelitis.

Main Methods:

• Literature review of clinical studies, diagnostic criteria, and pathogenetic research.
• Analysis of diagnostic approaches for differentiating SLE-related demyelination from MS.
• Discussion of specific CNS demyelinating conditions including transverse myelitis, optic neuritis, and neuromyelitis optica.

Main Results:

• Demyelinating syndromes in SLE present diagnostic challenges due to overlap with MS.
• Diagnostic tests aid in distinguishing between SLE-related and idiopathic demyelinating diseases.
• The precise role of antiphospholipid antibodies in SLE-associated transverse myelitis remains an area of active research.

Conclusions:

• Accurate differentiation of CNS demyelinating disease in SLE from MS is essential for appropriate management.
• Further research is needed to clarify the pathogenesis and optimize treatment strategies for SLE-related neurological syndromes.
• Understanding the nuances of these conditions improves patient outcomes and diagnostic accuracy.